PNC-27 is a peptide developed using a p53-related component and investigated in cancer-cell models. Laboratory cell killing does not establish that a product bearing this name treats cancer in people.
What the research shows
A 2010 study examined membrane HDM-2 interactions; a 2024 paper investigated membrane and mitochondrial effects in cultured pancreatic cancer cells. These cited sources are mechanistic studies, not clinical efficacy trials in patients. [1] [2]
Distinguishing substances and products
Human cells can mean cultured cells rather than treated patients. Cell or animal results should not be used to propose replacing established cancer care.
Reading a specific brand’s label
Start with the exact substance and product name, then match the label to the manufacturer’s documents. This article does not establish Thai registration or current availability for an unspecified product.
Frequently asked questions
Do the cited papers establish cancer treatment efficacy?
No. They investigate cellular mechanisms, not treatment efficacy in patients.
Does human cancer cells mean a human trial?
No. It can refer to human-derived cells grown in a laboratory.
What information helps identify a specific product?
The brand, product name, full label and matching manufacturer documents. Evidence about the substance alone does not establish a product’s identity, registration or quality.
Related information
For general questions about names or label details, contact LINE: @musclestationth
Sources and review date
- Sarafraz-Yazdi et al., 2010 — PNC-27 cell mechanisms
- Krzesaj et al., 2024 — membrane and mitochondrial study
Sources checked: 11 September 2026. This page explains selected primary sources; it is not a systematic review of every study.